Abstract: An sDR5-Fc recombinant fusion protein having amino acid sequence of SEQ ID NO: 2 and a gene encoding the protein and having a nucleotide sequence as shown in SEQ ID NO: 1 are provided. Further, applications of the protein and the gene in the preparation of medicament for preventing and treating autoimmune hepatitis or drug-induced liver injury are provided.
Abstract: Methods treating pulmonary hypertension, including pulmonary arterial hypertension, are provided, and include administering a polypeptide antagonist of a Na/K ATPase/Src receptor complex to a subject in need thereof. Administration of the polypeptide antagonist reduces pulmonary artery acceleration time, reduces an amount of right ventricular hypertrophy, reduces right ventricular wall thickness, reduces an amount of pulmonary vessel wall thickness, reduces an amount of plexiform lesions in a lung of the subject, reduces an amount of collagen deposition in a pulmonary blood vessel, reduces an amount of collagen deposition in a pulmonary blood vessel media or adventitia, and/or reduces an amount of right ventricular fibrosis. Methods of reducing pulmonary vessel wall thickness are also provided and include the administration of the polypeptide antagonist of a Na/K ATPase/Src receptor complex.
Type:
Grant
Filed:
May 11, 2018
Date of Patent:
January 11, 2022
Assignee:
MARSHALL UNIVERSITY RESEARCH CORPORATION
Inventors:
Zijian Xie, Jiayan Wang, Sandrine V. Pierre, Joseph I. Shapiro
Abstract: Compositions comprising bis(tryptophan) derivatives are provided that act as antimicrobials. Also provided are methods for reversing antibiotic resistance in a bacterium, or recovering or enhancing antimicrobial activity of an antibiotic against a variety of microbes, by co-administration with a bis(tryptophan) derivative.
Type:
Grant
Filed:
June 20, 2017
Date of Patent:
January 4, 2022
Assignee:
The Curators of the University of Missouri
Inventors:
George W Gokel, Joseph W Meisel, Mohit B Patel
Abstract: A zinc-alpha-2-glycoprotein (ZAG) protein-derived peptide according to the present invention shows an expression reducing effect of various immune factors shown in acute or chronic atopic dermatitis, and has a decreased immune response and decreased IgE expression and thus may be used to prevent, treat or improve xeroderma or an abnormal skin barrier function such as atopic dermatitis, an allergic disease or inflammation.
Type:
Grant
Filed:
September 28, 2018
Date of Patent:
January 4, 2022
Assignee:
L&C Bio Co., LTD.
Inventors:
Eun Seong Lee, Hyung Gu Kim, Whan Chul Lee, Kee Won Lee
Abstract: Provided is a method of regenerating cartilage tissues by treatment with hyaluronan and proteoglycan link protein 1 (HAPLN1), and a composition for regenerating cartilage, the composition including HAPLN1 as an active ingredient. According to the present disclosure, the HAPLN1 protein may have cartilage formation-stimulating ability and articular cartilage regeneration ability, may increase an expression level of TGF-? receptor I of chondrocytes to increase a component ratio of cells having cartilage formation ability, and to induce regeneration of cartilage tissues. Accordingly, the HAPLN1 protein of the present disclosure, which is a novel composition regulating TGF-? signaling, may be usefully applied as a pharmaceutical composition for regenerating cartilage, a health food composition for regenerating cartilage, or a reagent composition for regenerating cartilage.
Abstract: Compositions and methods for treating melanoma are provided. Compositions include BRAFV600E-based peptides, alone or admixed with T helper peptides. Other compositions include nucleic acid sequences encoding the BRAFV600E-based peptides, alone or admixed with nucleic acid sequences T helper peptides. Dendritic cells pretreated with the BRAFV600E-based peptides, alone or admixed with T helper peptides, are also provided. These compositions are useful to treat melanoma, optionally co-administered with antibodies to checkpoint inhibitors or molecules that mimic the action of such antibodies.
Type:
Grant
Filed:
February 16, 2017
Date of Patent:
December 28, 2021
Assignee:
The Wistar Institute of Anatomy and Biology
Abstract: Disclosed herein are methods for modifying ciliogenesis in one or more cells of a subject, the method comprising administering to the subject an effective amount of a composition comprising a Notch signaling inhibitor, wherein the modification results in an increase in a number of cilia, an increase in a length of cilia, and/or an increase in a beat frequency of cilia as compared to a control. Also disclosed herein are methods for modifying ciliogenesis in one or more cells of a subject, the method comprising administering to the subject from 0.1 ?g/kg to 100 g/kg of a Notch signaling inhibitor. In some embodiments, the methods can be used to treat Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Asthma, Primary Ciliary Dyskinesia (PCD), Cystic Fibrosis (CF), or hydrocephalus.
Type:
Grant
Filed:
January 3, 2018
Date of Patent:
December 28, 2021
Assignee:
UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Abstract: A novel peptide which comprises an amino acid sequence represented by SEQ ID NO: 23, and specifically inhibits the protease activity of a target molecule.
Abstract: An object of the present invention is to provide a composition for preventing or improving fat deposition on the liver in spite of the alcohol intake history of a level that a liver disease is not caused. The inventors found that glutathione has an effect of preventing or improving fat deposition on the liver, which is not caused by alcohol, and completed the present invention. Among nonalcoholic fat diseases, the present invention is particularly effective in an early stage of the treatment or in a case where treatment for another disease is not performed.
Type:
Grant
Filed:
June 1, 2020
Date of Patent:
December 28, 2021
Assignees:
KOHJIN LIFE SCIENCES CO., LTD., PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY, KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, SAGA UNIVERSITY
Abstract: A peptide that includes a partial amino acid sequence of the C16orf74 protein, includes the cysteine at position 7 and/or the cysteine at position 14 of the C16orf74 protein, and inhibits dimer formation of the C16orf74 protein is provided. A pharmaceutical composition for cancer treatment that includes the peptide is also provided. A screening method for cancer treatment drugs that takes as the indicator inhibition of dimer formation of the C16orf74 protein is also provided.
Type:
Grant
Filed:
September 10, 2018
Date of Patent:
December 21, 2021
Assignee:
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
Abstract: Disclosed herein are composite polypeptide. According to various embodiments, the composite polypeptide includes a parent polypeptide and a metal binding motif capable of forming a complex with a metal cation. The composite polypeptide may be conjugated with a linker unit having a plurality of functional elements to form a multi-functional molecular construct. Alternatively, multiple composite polypeptides may be conjugated to a linker unit to form a molecular construct, or a polypeptide bundle. Linker units suitable for conjugating with the composite polypeptide having the metal binding motif are also disclosed.
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating neovascular disease, including a collagen and a 34-mer pigment epithelium derived factor (PEDF) peptide as an active ingredient, more specifically, the combined administration of the collagen type I and the 34-mer pigment epithelium derived factor peptide increases the short antiangiogenic activity cycle of the PEDF and extends the dosage range of the PEDF to solve the discomfort and the side effects accordingly due to the conventional frequent injections and thus it can be applied as a therapeutic agent for various neovascular diseases.
Type:
Grant
Filed:
June 8, 2018
Date of Patent:
December 14, 2021
Assignee:
NexThera Co., Ltd.
Inventors:
Sea Gwang Park, Kug Hwan Roh, Hyun Woong Kim, Sung Jae Park
Abstract: Long-term stable pharmaceutical formulations of lyophilized recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations are described.
Type:
Grant
Filed:
January 25, 2019
Date of Patent:
December 14, 2021
Assignee:
Takeda Pharmaceutical Company Limited
Inventors:
Kurt Schnecker, Eva Haidweger, Peter Turecek
Abstract: Disclosed herein are peptoids and methods for attenuating inflammatory responses, and more particularly RAGE-associated inflammatory responses.
Type:
Grant
Filed:
July 17, 2019
Date of Patent:
December 14, 2021
Assignees:
The Board of Trustees of the University of Arkansas, University of South Carolina
Inventors:
Shannon Servoss, Melissa Moss, Lauren Wolf
Abstract: Long-term stable pharmaceutical formulations of lyophilized recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations are described.
Type:
Grant
Filed:
January 25, 2019
Date of Patent:
December 7, 2021
Assignee:
Takeda Pharmaceutical Company Limited
Inventors:
Kurt Schnecker, Eva Haidweger, Peter Turecek
Abstract: An object of the present invention is to provide a peptide drug that is able to selectively induce apoptosis in target cells. The present invention is a cytocidal agent containing a fusion peptide of an endosome escape peptide and an apoptosis-inducing peptide, which consists of an amino acid sequence represented by SEQ ID NO: 1, and the said cytocidal agent as a therapeutic agent for a disease caused by abnormal proliferation of cells.
Abstract: The disclosure provides compositions and methods for treating, ameliorating, and/or preventing a vaso-occlusive crisis (VOC) in a subject suffering from sickle cell disease (SCD). The disclosure also provides compositions and methods for treating, ameliorating, and/or preventing lung injury in a subject suffering from or at risk of suffering from acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS). The disclosure provides A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, member-13 (ADAMTS13) or a composition comprising ADAMTS13 for treating, ameliorating, and/or preventing the VOC, or for treating, ameliorating, and/or preventing lung injury in a subject suffering from or at risk of suffering from ALI and/or ARDS.
Type:
Grant
Filed:
August 4, 2017
Date of Patent:
December 7, 2021
Assignee:
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors:
Bruce Ewenstein, Brahm Goldstein, Bernhard Majer, Paolo Rossato, Friedrich Scheiflinger, Marietta Turecek
Abstract: Simple ?-hairpin peptides in linear and cyclic form that specifically bind to HIV-1 Trans-Activation Response element (HIV-1 TAR), as well as compositions and use thereof are described.
Type:
Grant
Filed:
December 20, 2019
Date of Patent:
November 30, 2021
Assignees:
Colorado State University Research Foundation, University of Rochester
Inventors:
Brian R. McNaughton, David W. Crawford, Joseph E. Wedekind, Ivan A. Belashov
Abstract: A substance P analog having a progenitor cell or stem cell recruiting activity and a method of recruiting progenitor cells or stem cells using the substance P analog are disclosed. The substance P analog has an effect of recruiting endogenous progenitor cells or stem cells to a wound or disease-occurring site. Thus, the disclosure also describes its use in recruiting progenitor cells or stem cells and a method of regenerating or treating a damaged organ or tissue, or a method of healing a wound.
Type:
Grant
Filed:
April 24, 2020
Date of Patent:
November 30, 2021
Assignee:
AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Inventors:
Moon Suk Kim, Sang Dun Choi, Seung Hun Park, Masaud Shah